Delayed classic and protracted phenotypes of compound heterozygous juvenile neuronal ceroid lipofuscinosis

Neurology

Volumn 52, Issue 2, 1999, Pages 360-365

  Lauronen, Leena ^c   Munroe, P B ^b   Jarvela I ^a   Autti, T ^d   Mitchison, H M ^b   O'Rawe, A M ^b   Gardiner, R M ^b   Mole, S E ^b   Puranen, J ^d   Hakkinen A M ^d   Kirveskari, E ^d   Santavuori, P ^d  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLINDNESS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EVOKED SOMATOSENSORY RESPONSE; EXON; FEMALE; FINLAND; GENE DELETION; GENOTYPE; HETEROZYGOSITY; HUMAN; MALE; MENTAL DISEASE; MISSENSE MUTATION; MOTOR DYSFUNCTION; NEURONAL CEROID LIPOFUSCINOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; WHITE MATTER;

EID: 0033555573     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.2.360     Document Type: Article

References (25)

1. Sjögren T. Die juvenile amaurotische Idiotie. Klinische und erblichkeitsmedizinische Untersuchungen. Lund: Hereditas 1931;14:197-426.
2. Zeman W, Donohue S, Dyken P, Green J. The neuronal ceroidlipofuscinoses (Batten-Vogt syndrome). In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology. Vol. 10. Amsterdam: North Holland Publishing, 1970:588-679.
3. International Batten Disease Consortium. Isolation of a novel gene underlying Batten disease, CLN3. Cell 1995;82:949-957.
4. Järvelä I, Sainio M, Rantamäki T, et al. Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease. Hum Mol Genet 1998;7:85-90.
5. Munroe PB, Mitchison HM, O'Rawe AM, et al. Spectrum of mutations in the Batten disease gene, CLN3. Am J Hum Genet 1997;61:310-316.
6. Järvelä I, Mitchison HM, Munroe PB, O'Rawe AM, Mole SE, Syvänen AC. Rapid diagnostic test for the major mutation underlying Batten disease. J Med Genet 1996;33:1041-1042.
7. Järvelä I, Autti T, Lamminranta S, Åberg L, Raininko R, Santavuori P. Clinical and magnetic resonance imaging findings in Batten disease: analysis of the major mutation (1.02-kb deletion). Ann Neurol 1997;42:799-802.
8. Libert J, Martin JJ, Ceuterick C. Protracted and atypical forms of ceroid-lipofuscinosis. In: Armstrong D, Koppang N, Rider JA, eds. Ceroid-lipofuscinosis (Batten's disease). Amsterdam: Elsevier Biomedical Press, 1982:45-59.
9. Goebel HH, Pilz H, Gullotta F. The protracted form of juvenile neuronal ceroid-lipofuscinosis. Acta Neuropathol (Berl) 1976; 36:393-396.
10. Wisniewski KE, Zhong N, Kaczmarski W, et al. Compound heterozygous genotype is associated with protracted juvenile neuronal ceroid lipofuscinosis. Ann Neurol 1998;43:106-110.
11. Rapola J. Neuronal ceroid-lipofuscinoses in childhood. In: Landing BH, Haust MD, Bernstein J, Rosenberg HS, eds. Genetic metabolic diseases. Perspectives in pediatric pathology. Basel: Karger, 1993:7-44.
12. Raitta C, Santavuori P. Ophthalmological findings and main clinical characteristics in childhood types of neuronal ceroidlipofuscinosis. In: Huber K, Klein D, eds. Neurogenetics and neuro-ophthalmology. Amsterdam: Elsevier Biomedical Press, 1981:307-316.
13. Santavuori P, Heiskala H, Westermarck T, Sainio K, Moren R. Experience over 17 years with antioxidant treatment in Spielmeyer-Sjögren disease. Am J Med Genet 1988;5:265-274.
14. Mitchison HM, Munroe PB, O'Rawe AM, et al. Genomic structure and complete nucleotide sequence of the Batten disease gene, CLN3. Genomics 1997;40:346-350.
15. Autti T, Raininko R, Vanhanen S-L, Santavuori P. MRI of neuronal ceroid lipofuscinosis I. Cranial MRI of 30 patients with juvenile neuronal ceroid lipofuscinosis. Neuroradiology 1996;38:476-482.
16. Hämäläinen M, Hari R, Ilmoniemi RJ, Knuutila J, Lounasmaa OV. Magnetoencephalography - theory, instrumentation, and applications to noninvasive studies of the working human brain. Rev Mod Phys 1993;65:413-497.
17. Lauronen L, Heikkilä E, Autti T, et al. Somatosensory evoked magnetic fields from primary sensorimotor cortex in juvenile neuronal ceroid lipofuscinosis. J Child Neurol 1997;12: 355-360.
18. Rechtschaffen A, Kales A. Manual of standardized terminology, techniques and scoring system of sleep stages of human subjects. Los Angeles: Brain Information Service/Brain Research Institute, University of California, 1968.
19. Munroe PB, O'Rawe AM, Mitchison HM, et al. Strategy for mutation detection in CLN3: characterisation of two Finnish mutations. Neuropediatrics 1997;28:15-17.
20. Majander A, Pihko H, Santavuori P. Palmitate oxidation in muscle mitochondria of patients with the juvenile form of neuronal ceroid-lipofuscinosis. Am J Med Genet 1995;57:298-300.
21. Janes RW, Munroe PB, Mitchison HM, Gardiner RM, Mole SE, Wallace BA. A model for Batten disease protein CLN3: functional implications from homology and mutations. FEBS Lett 1996;399:75-77.
22. Autti T, Raininko R, Santavuori P, Vanhanen S-L, Poutanen V-P, Haltia M. MRI of neuronal ceroid lipofuscinosis II. Postmortem MRI and histopathological study of the brain in 16 cases of neuronal ceroid lipofuscinosis of juvenile or late infantile type. Neuroradiology 1997;39:371-377.
23. Berkovic SF, So NK, Andermann F. Progressive myoclonus epilepsies: clinical and neurophysiological diagnosis. J Clin Neurophysiol 1991;8:261-274.
24. Karhu J, Hari R, Paetau R, Kajola M, Mervaala E. Cortical reactivity in progressive myoclonus epilepsy. Electroencephalogr Clin Neurophysiol 1994;90:93-102.
25. Uesaka Y, Ugawa Y, Yumoto M, Sakuta M, Kanazawa I. Giant somatosensory evoked magnetic field in patients with myoclonus epilepsy. Electroencephalogr Clin Neurophysiol 1993;87:300-305.